Previous studies conducted on AD mouse models illustrated that Tau-targeted therapies also lead to Aβ-related cognitive deficit improvements, indirectly highlighting the toxic combination between Aβ and Tau [97]. The gene discussed is MAPT; the disease is Alzheimer disease.